OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Drug Discovery is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)

Article	Citations
Lessons learned from phenotypic drug discovery efforts	139
An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19)	95
Strategies for targeting RNA with small molecule drugs	78
Advances in the discovery of drugs that treat pulmonary arterial hypertension	74
Advances in ion channel high throughput screening: where are we in 2023?	73
Reality check: lipid-oligonucleotide conjugates for therapeutic applications	71
What is the plausibility that all drugs will be designed by computers by the end of the decade?	61
γ-Secretase: once and future drug target for Alzheimer’s disease	60
Scaffold hopping approaches for dual-target antitumor drug discovery: opportunities and challenges	57
Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery	54
Methods in marine natural product drug discovery: what’s new?	47
A comprehensive update on the use of molecular topology applications for anti-infective drug discovery	45
Tools and techniques for the discovery of therapeutic aptamers: recent advances	38
The rules often neglected in current medicinal chemistry	37
A cautionary tale of paradox and false positives in cannabidiol research	37
Understanding the impact of binding free energy and kinetics calculations in modern drug discovery	37
Virtual screening: hope, hype, and the fine line in between	36
Water in drug design: pitfalls and good practices	36
C. elegans : a prominent platform for modeling and drug screening in neurological disorders	30
Guided structure-based ligand identification and design via artificial intelligence modeling	30
An update on knowledge graphs and their current and potential applications in drug discovery	30
Calcium channel blockers’ contribution to overcoming Current drug discovery challenges in Alzheimer’s disease	30
Molecular hybridization: a powerful tool for multitarget drug discovery	29
Acoustic ejection mass spectrometry: fundamentals and applications in high-throughput drug discovery	29
Novel hydrogels: are they poised to transform 3D cell-based assay systems in early drug discovery?	28

Correction	27
Revisiting experimental models of erectile dysfunction and their value in drug discovery and development	26
Current challenges and future perspectives of drug discovery in China	26
Animal models of chronic obstructive pulmonary disease and their role in drug discovery and development: a critical review	26
Innovative strategies for the discovery of new drugs against alopecia areata: taking aim at the immune system	25
Murine models of dengue virus infection for novel drug discovery	25
Drug design strategies for the treatment azole-resistant candidiasis	25
The discovery and development of RNA-based therapies for treatment of HIV-1 infection	25
Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer	24
Recent applications of positron emission tomographic (PET) imaging in psychiatric drug discovery	24
Lessons learned from the discovery and development of the sesquiterpene lactones in cancer therapy and prevention	23
Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach	22
Success stories of AI in drug discovery - where do things stand?	22
What are the challenges with multi-targeted drug design for complex diseases?	22
An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma	22
The design and discovery of phospholipase A₂ inhibitors for the treatment of inflammatory diseases	21
High performance-oriented computer aided drug design approaches in the exascale era	21
What have we learnt from past failures in Alzheimer’s disease drug discovery?	21
The application of pancreatic cancer organoids for novel drug discovery	21
Advances in the design, discovery, and optimization of aurora kinase inhibitors as anticancer agents	21
Mapping strategies towards improved external validity in preclinical translational research	20
A comprehensive update on the application of high-throughput fluorescence imaging for novel drug discovery	19
Advances in the discovery of new chemotypes through ultra-large library docking	19
Targeted Degradation of Structured RNAs via Ribonuclease-Targeting Chimeras (RiboTacs)	18
Designing multi-target drugs for the treatment of major depressive disorder	18
PTPN22: structure, function, and developments in inhibitor discovery with applications for immunotherapy	18
Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies	17
Metabolomics in antimicrobial drug discovery	17
The human NTG model of migraine in drug discovery and development	17
Avenues for antifungal drug discovery and development: where to now?	17
Unmasking allosteric-binding sites: novel targets for GPCR drug discovery	17
Latest developments in engineered skeletal muscle tissues for drug discovery and development	16
How do we address neglected sulfur pharmacophores in drug discovery?	16
Data processing for high-throughput mass spectrometry in drug discovery	16
An overview on small molecules acting as broad-spectrum agents for yellow fever infection	16
Advances in structure-activity relationships of HDAC inhibitors as HIV latency-reversing agents	16
Novel avenues for identification of new antifungal drugs and current challenges	16
In silico drug design strategies for discovering novel tuberculosis therapeutics	16
Targeting protein-protein interactions with low molecular weight and short peptide modulators: insights on disease pathways and starting points for drug discovery	15
The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: is it really that simple?	15
The role of rodent behavioral models of schizophrenia in the ongoing search for novel antipsychotics	15
Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis	15
What is the future of click chemistry in drug discovery and development?	15
Efflux in Gram-negative bacteria: what are the latest opportunities for drug discovery?	15
The discovery and development of novel treatment strategies for filoviruses	15
Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer’s disease	15
The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma	15
Future prospects of accelerating neuroactive drug discovery with high-throughput behavioral phenotyping	15
The preclinical discovery and development of zanubrutinib for the treatment of chronic lymphocytic leukemia	14
The problem of antimalarial resistance and its implications for drug discovery	14

The latest advances in high content screening in microfluidic devices	14
Artificial intelligence for small molecule anticancer drug discovery	14
Long non-coding RNA-targeting therapeutics: discovery and development update	13
Recent animal models of bladder cancer and their application in drug discovery: an update of the literature	13
Have spirocyclic scaffolds been properly utilized in recent drug discovery efforts?	13
Understanding the role of cGAS-STING signaling in ischemic stroke: a new avenue for drug discovery	13
Investigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches	13
Strategies for the drug discovery and development of taxane anticancer therapeutics	13
Library size in virtual screening: is it truly a number’s game?	13
An overview of rational design of mRNA-based therapeutics and vaccines	13
Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism	12
3D bioprinting for organ and organoid models and disease modeling	12
An update on preclinical pregnancy models of Zika virus infection for drug and vaccine discovery	12
Validation guidelines for drug-target prediction methods	12
Current views on in vivo models for breast cancer research and related drug development	12
Preclinical models of insomnia: advances, limitations, and future directions for drug discovery	12
Targeting guanine nucleotide exchange factors for novel cancer drug discovery	12
Challenges with the discovery of RNA-based therapeutics for flaviviruses	12
The design and discovery of topoisomerase I inhibitors as anticancer therapies	12
Molecular glue degraders: exciting opportunities for novel drug discovery	12
Animal models of Kabuki syndrome and their applicability to novel drug discovery	12
Is it possible to design a clinically viable heroin vaccine? The progress and pitfalls	11
Fragment-based approaches to discover ligands for tumor-specific E3 ligases	11
Open resources for chemical probes and their implications for future drug discovery	11
An overview of the latest in state-of-the-art murine models for prostate cancer	11
Notice of duplicate publication: What are the practical, ethical and pathobiological considerations in the use of minipigs as an animal model in drug discovery for acute radiation syndrome and delayed	11
Designing drugs when there is low data availability: one-shot learning and other approaches to face the issues of a long-term concern	11
Perspectives on the success of plasma lipidomics in cardiovascular drug discovery and future challenges	11
Advances in the design and discovery of next-generation janus kinase-2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasms	11
Recent advances in cellular models for discovering prion disease therapeutics	11
Using automated patch clamp electrophysiology platforms in ion channel drug discovery: an industry perspective	11
Linkers in fragment-based drug design: an overview of the literature	11
Lessons learnt from machine learning in early stages of drug discovery	11